HIV Infections Clinical Trial
Official title:
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir (TDF) in HIV-HBV co-Infected Patients
Human immunodeficiency virus/Hepatitis B virus (HIV/HBV) co-infections are frequently observed due to shared routes of transmission, with reported figures indicating 6-9% of HIV-infected individuals in developed countries are chronically infected with HBV. HIV infection impacts on the natural progression of HBV infection, increasing levels of HBV replication and the risk of liver-associated mortality. Liver diseases associated with HBV are affected by the antiviral drugs used for HIV infection (toxic side effects), the current immune function in the patient, by improvements in the immune system brought about by control of the HIV infection, and by the development of resistance to the antiviral agents used for both the hepatitis B and the HIV infection. Tenofovir (TDF) is a newer antiviral drug that is frequently used for HIV infection and is also highly active against hepatitis B; however it is still unknown whether resistance to TDF will eventually develop and how this will affect the long-term outcomes
Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue that can inhibit both HIV and
HBV DNA polymerases, and is active against wild-type HBV and HBV strains that contain
lamivudine-associated polymerase gene mutations (Dore, Cooper et al. 2004). TDF was approved
for use, in combination with other antiretrovirals, for HIV therapy in April 2002 in
Australia. It is not currently approved for use in Australia for treatment of HBV
mono-infection. TDF has only recently become available in Thailand where HIV/HBV co-infected
individuals are predominantly infected with genotype B and C. In contrast, in Australia and
Europe, the dominant HBV genotype in HIV/HBV co-infected individuals is A and D. As with all
antiviral agents there is concern with long-term use and the development of resistance.
There has been a report of a signature mutation leading to TDF resistance at rtA194T
(Sheldon et al., 2005). We recently conducted a retrospective study of HIV/HBV co infected
individuals in Melbourne who had received TDF for at least 3 months. Twenty-eight patients
had samples available on TDF of which four (~14%) had detectable HBV DNA by PCR. We did not
identify the mutation rtA194T or rtV214A/Q215S in individuals failing TDF and found that the
only persisting mutations were LMV-resistant mutations. These findings highlight the need
for a surveillance system for HIV-HBV co-infected individuals receiving TDF for the
detection of novel mutations in the four major HBV genotypes. In addition, it is important
to determine the clinical and virological risk factors for TDF failure. This is particularly
important given that these agents will be used indefinitely in this patient population and
with the development of unique drug resistant mutations there will be implications for
progression of liver disease and future therapeutic choices.
This study will recruit patients who are co-infected with HIV and HBV, and are currently
taking or who are about to commence the anti-HIV drug TDF. The study cohort will include
HIV-HBV co-infected individuals from the Alfred Hospital and Melbourne Sexual Health Clinic.
Other sites, not covered by this application, are St Vincent's Hospital, Sydney and King
Chulalongkorn Memorial Hospital, Bangkok, Thailand.
The aim of the study is to identify any changes in the HBV DNA that might be associated with
resistance to TDF, to determine how long any changes take to occur and to determine the
effect of these changes on the clinical response to TDF.
This will be achieved by 6 monthly assessment over a 2 year period, with medical history,
physical examination, routine clinical investigations, hepatitis B activity and HBV DNA
sequencing.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |